116 related articles for article (PubMed ID: 38588328)
1. Enhanced Theranostic Efficacy of
Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
[TBL] [Abstract][Full Text] [Related]
2. Theranostic role of
Yang Q; Chen Z; Qiu Y; Huang W; Wang T; Song L; Sun X; Li C; Xu X; Kang L
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1246-1260. PubMed ID: 38135849
[TBL] [Abstract][Full Text] [Related]
3.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
4. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
7. CD38-Targeted Theranostics of Lymphoma with
Kang L; Li C; Rosenkrans ZT; Huo N; Chen Z; Ehlerding EB; Huo Y; Ferreira CA; Barnhart TE; Engle JW; Wang R; Jiang D; Xu X; Cai W
Adv Sci (Weinh); 2021 May; 8(10):2001879. PubMed ID: 34026426
[TBL] [Abstract][Full Text] [Related]
8. Proof of Therapeutic Efficacy of a
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
10. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
11. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
[TBL] [Abstract][Full Text] [Related]
12. Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.
Meyer JP; Edwards KJ; Kozlowski P; Backer MV; Backer JM; Lewis JS
J Nucl Med; 2016 Nov; 57(11):1811-1816. PubMed ID: 27390161
[TBL] [Abstract][Full Text] [Related]
13. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
14. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeling of PSMA-617 with
Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
[TBL] [Abstract][Full Text] [Related]
16. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
17.
Giesen D; Hooge MNL; Nijland M; Heyerdahl H; Dahle J; de Vries EGE; Pool M
Sci Rep; 2022 Apr; 12(1):6286. PubMed ID: 35428777
[TBL] [Abstract][Full Text] [Related]
18. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of [
Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
[TBL] [Abstract][Full Text] [Related]
20. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
